Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category. Sangamo Biosciences does not face any business risks ...

Wells Fargo analyst Yanan Zhu assigned a Hold rating to Sangamo Biosciences (SGMO – Research Report) yesterday and set a price target of ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.

As of the latest trading close, SGMO, a Healthcare sector stock, is trading -18.26% below its 52-week high but remains 545.83% above its 52-week low. The Average True Range (ATR) (14 days) of 0.23 ...

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

Shares of SGMO stock opened at $2.87 on Monday. The firm has a fifty day simple moving average of $1.16 and a 200-day simple moving average of $0.80. The company has a market capitalization of $ ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $5.00 to $10.00. HC ...

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

On a per-share basis, the Richmond, California-based company said it had profit of 4 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...